{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:38:01Z","timestamp":1791841081765,"version":"4.3.4"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T00:00:00Z","timestamp":1355875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aim<\/jats:title><jats:p>Worldwide anti\u2010tuberculosis (<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>) drug\u2010induced liver disease (<jats:styled-content style=\"fixed-case\">DILI<\/jats:styled-content>) is an important cause of hepatotoxicity, and drug\u2010induced acute liver failure (<jats:styled-content style=\"fixed-case\">ALF<\/jats:styled-content>). Reported series on anti\u2010<jats:styled-content style=\"fixed-case\">TB DILI<\/jats:styled-content> are limited by a mix of cases with mild transaminase elevation or adaptation. Our aim was to analyze the clinical features, laboratory characteristics, outcome, and determine predictors of 90\u2010day mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Single center analysis of consecutive cases of anti\u2010<jats:styled-content style=\"fixed-case\">TB DILI<\/jats:styled-content> following combination anti\u2010<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> drugs exposure from 1997\u20132011.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 269 patients, 191 (71%) experienced jaundice and 69 (25.7%) accounted for <jats:styled-content style=\"fixed-case\">ALF<\/jats:styled-content>. The mean age and treatment duration was 41.3 years and 1.9 months, respectively; males constituted 55.7%. <jats:styled-content style=\"fixed-case\">DILI<\/jats:styled-content> occurred throughout the course of treatment; three\u2010quarters occurred within the first 2\u2009months. <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> infection was present in 21 (7.8%). The 90\u2010day mortality was 22.7%. <jats:styled-content style=\"fixed-case\">DILI<\/jats:styled-content> accompanied by jaundice (<jats:italic>n<\/jats:italic>\u2009=\u2009191), encephalopathy (<jats:italic>n<\/jats:italic>\u2009=\u200969) or ascites (<jats:italic>n<\/jats:italic>\u2009=\u200969) resulted in mortality in 30%, 69.6% and 50.7%, respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Age, gender, transaminase levels, <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> or hepatitis B surface antigen (<jats:styled-content style=\"fixed-case\">HBsAg)<\/jats:styled-content> status did not influence survival. Treatment duration, encephalopathy, ascites, bilirubin, serum albumin, international normalized ratio (<jats:styled-content style=\"fixed-case\">INR)<\/jats:styled-content>, serum creatinine and leukocyte count were associated with mortality (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Multivariate logistic regression model for mortality, incorporating encephalopathy, albumin, bilirubin, <jats:styled-content style=\"fixed-case\">INR<\/jats:styled-content>, and creatinine yielded a <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\u2010statistic of 97%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Anti\u2010<jats:styled-content style=\"fixed-case\">TB DILI<\/jats:styled-content> occurs throughout treatment duration progressing to <jats:styled-content style=\"fixed-case\">ALF<\/jats:styled-content> in a quarter of patients. The overall mortality is 22.7%, which is higher when accompanied by jaundice, ascites or encephalopathy. An anti\u2010<jats:styled-content style=\"fixed-case\">TB DILI<\/jats:styled-content> model, incorporating bilirubin, <jats:styled-content style=\"fixed-case\">INR<\/jats:styled-content>, encephalopathy, serum creatinine and albumin predicted mortality with <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\u2010statistic of 97%.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1440-1746.2012.07279.x","type":"journal-article","created":{"date-parts":[[2012,9,30]],"date-time":"2012-09-30T13:40:29Z","timestamp":1349012429000},"page":"161-167","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Outcome and determinants of mortality in 269 patients with combination anti\u2010tuberculosis drug\u2010induced liver injury"],"prefix":"10.1111","volume":"28","author":[{"given":"Harshad","family":"Devarbhavi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology St. John's Medical College Hospital  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvir","family":"Singh","sequence":"additional","affiliation":[{"name":"Cardiology Research Center Hamad Medical Corporation  Doha Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallikarjun","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology St. John's Medical College Hospital  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Sheth","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology St. John's Medical College Hospital  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channagiri Krishnamurthy","family":"Adarsh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology St. John's Medical College Hospital  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girisha","family":"Balaraju","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology St. John's Medical College Hospital  Bangalore India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,19]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"World Health Organization Report2011. Global tuberculosis control."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2010.134"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.2.231"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021836"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09102026"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/422645"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2301002"},{"key":"e_1_2_6_12_1","first-page":"995","article-title":"Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics","volume":"6","author":"Lee AM","year":"2002","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200802-355OC"},{"key":"e_1_2_6_14_1","first-page":"534","article-title":"Severe hepatotoxicity due to anti\u2010tuberculosis drugs in Spain","volume":"9","author":"Tost JR","year":"2005","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24527"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.287"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23534"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90468-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.006"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210407"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.011"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/518660"},{"key":"e_1_2_6_23_1","first-page":"A116","article-title":"Fulminant hepatic failure: cause, course and predictors of outcome","volume":"24","author":"Devarbhavi H","year":"2005","journal-title":"Ind. J. Gastroenterol."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91736-6"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225020-00005"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/650576"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.22172"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23805"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(90)90124-A"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000269104.22502.d2"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20948"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181709464"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23317"},{"key":"e_1_2_6_36_1","volume-title":"Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver","author":"Zimmerman HJ","year":"1999"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.7.536"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.262"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0850OC"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.04048.x"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1014"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.11.1445"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32102"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2012.07279.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2012.07279.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T02:19:50Z","timestamp":1697336390000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2012.07279.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,19]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1440-1746.2012.07279.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2012.07279.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,19]]},"assertion":[{"value":"2012-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}